women and recommended to 5% of women with high-risk medical conditions or taking a teratogenic medication. The risks of pregnancy or medication were rarely documented. CONCLUSION: While non-gynecologic specialists feel that contraceptive counseling is their responsibility, they do not routinely document counseling nor refer them to a gynecologist. OB and MFMs must provide more outreach to subspecialists who care for these women to help prevent unintended pregnancies in women at high risk of perinatal morbidity. Hadassah Medical Center, Jerusalem, Israel OBJECTIVE: Gestational thrombocytopenia (GT) accounts for 75% of cases of thrombocytopenia in pregnancy. In most cases of GT, thrombocytopenia is mild (100-150 X 10 9 /L) and has no consequences for either the mother or the fetus. We aimed to investigate the characteristics, neonatal risk and recurrence rate of GT with a platelet count <100 X 10 9 /L. STUDY DESIGN: We reviewed the records of women who delivered during 2006-2016 at a large tertiary care university hospital, and who had platelet count <100 X 10
(32%) as new-onset immune-thrombocytopenic purpura (ITP). The proportions of women with onset of thrombocytopenia in early pregnancy (P¼0.004) and a lower maternal nadir platelet count (P¼0.01) were higher among those with new-onset ITP than GT. Neonatal thrombocytopenia (<100 X 10 9 /L) was encountered following comparable proportions of pregnancies of women with new-onset ITP and GT (16.1% vs. 10.6%, P¼0.51). Among women with GT, the rate of neonatal thrombocytopenia was higher in those who experienced antepartum bleeding (P¼0.009) and in whom the onset of thrombocytopenia was in early pregnancy (P¼0.002). Of 40 subsequent pregnancies, a recurrence of GT (<100 X 10 9 /L) was encountered in 22 (55%), with similar maternal and perinatal outcomes compared to the initial pregnancy. CONCLUSION: The risk of neonatal thrombocytopenia was substantial and similar in GT and new-onset ITP. The recurrence rate of GT was high in subsequent pregnancies.
822 The effect of surgery-to-conception interval on pregnancy outcomes after sleeve gastrectomy 
OBJECTIVE:
The optimal timing of pregnancy following bariatric surgery has not been established, with data limited regarding laparoscopic sleeve gastrectomy (LSG). We aimed to explore associations of the surgery-to-conception interval with pregnancy outcomes after LSG. STUDY DESIGN: We assessed pregnancy outcomes in relation to the surgery-to-conception interval for all women who underwent LSG and delivered during 2006-2018 in a university hospital. RESULTS: Of 154 patients, 67 (43.5%) conceived within the first 18 months postoperatively (early pregnancy group), whereas 87 (56.5%) conceived later (late pregnancy group). The median surgery-to-conception interval was 699 [interquartile range days. Baseline characteristics were comparable between the groups. Compared to the early pregnancy group, for the late pregnancy group, gestational weight gain was higher (median 11 vs. 8 kg, P<0.001), and hemoglobin levels were lower in early pregnancy (P¼0.03) and after delivery (P¼0.02). Other maternal and perinatal outcomes were similar between the groups, including the proportions of low-birth weight (7.5 vs. 11.5%, P¼0.58) and small-forgestational-age (SGA) infants (11.9% vs. 14.9%, P¼0.64) for those who conceived within or later than 18 months after surgery. The delivery of a SGA infant was not found to associate with any of the patient characteristics assessed, including the surgery-to-conception time interval (P¼0.30) and gestational weight gain (P¼0.14). CONCLUSION: Timing of pregnancy after LSG was found not to be associated with pregnancy outcomes. Together with documentations of a similar safety profile of pregnancy occurring earlier or later in the postoperative course, these data should reassure women who wish not to delay conception following surgery. Baseline characteristics were comparable between the groups except for a higher proportion of nulliparity among those with new-onset disease (P¼0.002). Maternal nadir platelet count was significantly lower among those with new-onset compared to previously diagnosed ITP (median 62 X 10 9 /L vs. 81 X 10 9 /L, P¼0.005). Neonatal thrombocytopenia (<150 X 10 9 /L) was encountered in 24 (9.5%) pregnancies, and required treatment in 12 (50%) of them. Neonatal platelet count was directly correlated with maternal platelet count at delivery (r¼0.23, P¼0.01), with significantly lower maternal platelet count among those whose newborns experienced thrombocytopenia (P<0.001). Neonatal thrombocytopenia followed a higher proportion of pregnancies of women with new-onset than previously diagnosed ITP (22.6% vs. 7.7%, P¼0.02). In multivariate analysis, the presence of new-onset ITP (odds ratio [95% CI]: 4.88 (1.68, 14.16), P¼0.004) was the only independent predictor of the development of neonatal thrombocytopenia. CONCLUSION: Neonatal thrombocytopenia presented following almost one-tenth of pregnancies with ITP. New pregnancy-onset disease was the only prognostic marker for neonatal thrombocytopenia. This finding could contribute to risk stratification and individualized patient management.
824 Maternal congenital heart defects and long-term cardiovascular morbidity of the offspring OBJECTIVE: Due to advances in medical care available for patients with congenital heart disease (CHD), these patients now have a longer life span. As a result, the number of pregnancies of mothers with CHD has increased. The purpose of the current study was to examine a possible association between being born to a mother with CHD and long-term cardiovascular morbidity of the offspring. STUDY DESIGN: A population-based cohort analysis was performed including all singleton deliveries occurring between years 1991-2014 at a single tertiary medical center.The primary exposure was defined as being born to a mother with CHD. Offspring of mothers without CHD comprised the comparison (unexposed) group. The main outcome evaluated was cardiovascular morbidity of the offspring up to the age of 18 years. A Kaplan-Meier survival curve was used to compare cumulative cardiovascular morbidity incidence. A Cox proportional hazards model was conducted to control for confounders. RESULTS: During the study period 242,342 deliveries met the inclusion criteria, of which 0.2% (n¼ 368) were of mothers who had CHD. Long-term cardiovascular morbidity was comparable between offspring to women with and without CHD (1.1% vs. 0.6%, respectively, p¼0.298; Table) . However, offspring of mothers with CHD had higher rates of hypertensive disorders during childhood (0.5% vs. 0.1%; p¼0.021). The Kaplan-Meier survival curve did not demonstrate a significantly higher cumulative incidence of cardiovascular morbidity in offspring of women with CHD ( Figure, log rank p¼0.251). In the Cox regression model, while controlling for confounders such as maternal age, preterm birth, gestational diabetes mellitus and hypertensive disorders of pregnancy, delivery of a neonate to mother with CHD was not found to be independently associated with long-term cardiovascular morbidity of the offspring. CONCLUSION: Offspring of women who have congenital heart disease are not at an increased risk for long-term cardiovascular morbidity. OBJECTIVE: Women with liver transplant may be at increased risk for maternal complications, but outcomes are not well characterized. The objective of this study was to characterize maternal risk for women with liver transplants. STUDY DESIGN: This retrospective cross sectional study utilized the Nationwide Inpatient Sample from the Healthcare Cost and Utilization Project from 1998 to 2014. Women age 15 to 54 admitted for a delivery hospitalization were included and categorized on the basis of having had a liver transplantation. Trends in risk for (i) severe maternal morbidity (SMM) based on CDC criteria, (ii) liver rejection, and (ii) coagulopathy were analyzed. Given that transfusion is
Delivery outcomes for women with liver transplants

